MRS can detect brain tumor biomarker

Many patients with a form of brain cancer called glioma have mutations in two genes that code for enzymes, IDH1 and IDH2. These changes result in increased levels of a compound called 2-hydroxyglutarate (2HG), seen in 80% of low- and intermediate-grade gliomas, and this biomarker can be detected using magnetic resonance spectroscopy (MRS). In a technical report published in Nature Medicine, researchers from University of Texas Southwestern Medical Center confirmed the technique's efficacy by analyzing tumors from 30 patients. They suggested that 2HG could be a valuable diagnostic and prognostic biomarker, as patients with this mutation tend to have better outcomes. Article | Abstract

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.